Skip to content

pharmaceuticals.co.nz

Drugs, medicines and medical news
Main navigation

Category: Parkinson’s disease

MJFF awards $6m to Lario Therapeutics for Parkinson’s research

MJFF awards m to Lario Therapeutics for Parkinson’s research
p p Read More

The neurological disease is estimated to affect more than ten million people globally

July 23, 2024 CaV2.3 calcium channel inhibition, Michael J. Fox Foundation, neurodegenerative diseases, neurological conditions, News, Parkinson's disease

Study finds Parkinson’s disease SLT more effective than one used in NHS

Study finds Parkinson’s disease SLT more effective than one used in NHS
p p Read More

The progressive neurodegenerative condition affects around 153,000 people in the UK

July 16, 2024 Lee Silverman Voice Treatment, neurodegenerative conditions, News, Parkinson's disease, PD-COMM, speech and language therapy, University of Birmingham, University of Nottingham

Mission awarded $5.2m to advance potential Parkinson’s treatment

Mission awarded .2m to advance potential Parkinson’s treatment
p p Read More

The progressive neurodegenerative condition affects around 153,000 people in the UK

July 8, 2024 Michael J. Fox Foundation, Mission Therapeutics, MTX325, neurodegenerative diseases, News, Parkinson's disease, Parkinson’s UK

Herantis Pharma granted €3.6m to assess treatment for Parkinson’s disease

Herantis Pharma granted €3.6m to assess treatment for Parkinson’s disease
p p Read More

The progressive neurological condition affects around 153,000 people in the UK

July 4, 2024 HER-096, Herantis Pharma, Michael J. Fox Foundation, News, Parkinson's disease, Parkinson's UK Virtual Biotech Programme

Parkinson’s UK awards ICL £100,000 to develop small drugs for Parkinson’s disease

Parkinson’s UK awards ICL £100,000 to develop small drugs for Parkinson’s disease
p p Read More

The neurodegenerative condition currently affects around 153,000 people in the UK

June 28, 2024 brain simulation, GPNMB, Imperial College London, neurodegenerative diseases, News, Parkinson's disease, Parkinson’s UK

US study suggests BMS’ cancer drug could target Parkinson’s-causing protein

US study suggests BMS’ cancer drug could target Parkinson’s-causing protein
p p Read More

The progressive neurodegenerative condition affects more than ten million people worldwide

June 20, 2024 Bristol Myers Squibb, Johns Hopkins Medicine, Lag3, neurodegenerative conditions, News, nivolumab/relatlimab, Opdualag, Parkinson's disease

LucyTx announces additional $12.5m research funding for neurological diseases

LucyTx announces additional .5m research funding for neurological diseases
p p Read More

Alzheimer’s and Parkinson’s disease are responsible for more than 30 million cases globally

June 11, 2024 Alzheimer's disease, Bill & Melinda Gates Foundation, Lucy Therapeutics, Michael J. Fox Foundation, neurological conditions, News, Parkinson's disease, Parkinson’s UK, Rett syndrome, Safar Partners

Cambridge researchers use AI to accelerate drug design for Parkinson’s disease

The progressive neurological condition affects more than six million people worldwide

May 1, 2024 artificial intelligence, drug discovery, Machine learning, News, Parkinson's disease, University of Cambridge

Researchers reveal people with Parkinson’s more likely to experience delirium in hospital

Two out of three people with the neurodegenerative condition experienced delirium in hospital

April 2, 2024 delirium, neurogenerative conditions, Newcastle University, News, Parkinson's disease, Parkinson’s UK

Parkinson’s UK grants funding of up to nearly £450,000 to four new research projects

The globally fast-growing progressive neurological condition affects around 153,000 people in the UK

March 21, 2024 King’s College London, London Metropolitan University, neurological diseases, News, Parkinson's disease, Parkinson’s UK, Robert Gordon University, University of Nottingham

Posts navigation

« Previous

Posts pagination

1 2 Next »
Proudly powered by WordPress | Theme: Hive Lite by Pixelgrade.
Footer navigation
  • Privacy Policy